Skip to main content

Table 2 Univariate analyses of the relationships between clinicopathologic factors and survival

From: Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma

Parameters N PFS OS
Months χ 2 P Months χ 2 P
Gender Male 55 4.433    7.400   
  Female 10 6.200 0.609 0.435 10.200 0.340 0.560
Age ≤50 22 4.000    5.867   
  >50 43 5.833 3.934 0.047 8.067 0.113 0.736
HBsAg Positive 55 4.433    6.467   
  Negative 10 5.833 0.516 0.472 8.800 3.608 0.057
AFP(IU/ml) ≤400 31 7.000    11.133   
  >400 34 4.233 3.016 0.082 5.200 5.236 0.022
Tumor number Single 18 5.600    8.967   
  >1 47 4.967 0.168 0.682 5.867 0.981 0.322
Tumor size(cm) ≤5 12 7.300    29.267   
  >5 53 4.367 3.792 0.051 5.867 9.834 0.002
Differentiation High 17 6.200    5.233   
  Middle 33 4.367    8.967   
  Low 15 4.000 3.630 0.163 5.667 3.097 0.213
Child-Pugh A 59 5.600    8.067   
  B 6 4.967 0.599 0.439 3.600 1.980 0.159
BCLC B 7 5.633    10.500   
  C 58 4.433 3.527 0.060 7.400 0.274 0.600
Hepatic cirrhosis Yes 34 4.967    6.533   
  No 31 4.433 0.002 0.965 8.967 0.194 0.659
Ascites Yes 14 4.367    5.000   
  No 51 5.600 2.706 0.100 8.967 3.887 0.049
Tumor thrombus Yes 28 3.000    5.000   
  No 37 5.833 2.800 0.094 11.367 8.067 0.005
Extrahepatic metastasis Yes 41 4.367    6.467   
  No 24 5.600 0.878 0.349 8.967 0.017 0.897
  1. PFS, progression-free survival; OS, overall survival; HbsAg, hepatitis B surface antigen; AFP, serum alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer stage.